Literature DB >> 23452319

Impact of a single human leucocyte antigen (HLA) allele mismatch on the outcome of unrelated bone marrow transplantation over two time periods. A retrospective analysis of 3003 patients from the HLA Working Group of the Japan Society for Blood and Marrow Transplantation.

Yoshinobu Kanda1, Junya Kanda, Yoshiko Atsuta, Yoshinobu Maeda, Tatsuo Ichinohe, Kazuteru Ohashi, Takahiro Fukuda, Koichi Miyamura, Hiroatsu Iida, Takehiko Mori, Koji Iwato, Tetsuya Eto, Keisei Kawa, Satoshi Morita, Yasuo Morishima.   

Abstract

A previous Japanese study revealed that a human leucocyte antigen (HLA)-A or -B allele mismatch was associated with higher overall mortality, whereas an HLA-C or -DRB1 allele mismatch did not affect mortality after serologically matched unrelated bone marrow transplantation (BMT). This study reanalysed 3003 adult patients who underwent unrelated BMT from a serologically HLA-A, -B, or -DR matched unrelated donor between 1993 and 2009 using the latest database, that included 1966 HLA-matched unrelated BMT and 187, 31, 524, and 295 unrelated BMT with a single HLA-A, -B, -C, or -DRB1 allele mismatch, respectively. As opposed to our previous findings, HLA-C and -DRB1 mismatches had a significant negative impact [hazard ratio (HR) 1·35, P < 0·001, and HR 1·45, P < 0·001] on survival in the period 2000-2009. The negative impact of each single HLA allele mismatch was not significantly different among the HLA-A, -B, -C, and -DRB1 mismatches (P = 0·79). An interaction test revealed that the effects of single HLA-C and -DRB1 allele mismatches significantly differed over the two time periods (P = 0·032 and P = 0·0072, respectively). In conclusion, the impact of a single HLA allele mismatch changed over time. In the recent cohort, the negative impact of HLA-DRB1 and -C mismatches became apparent.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23452319     DOI: 10.1111/bjh.12279

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  17 in total

1.  Impact of the presence of HLA 1-locus mismatch and the use of low-dose antithymocyte globulin in unrelated bone marrow transplantation.

Authors:  K Kawamura; J Kanda; S Fuji; M Murata; K Ikegame; K Yoshioka; T Fukuda; Y Ozawa; N Uchida; K Iwato; T Sakura; M Hidaka; H Hashimoto; T Ichinohe; Y Atsuta; Y Kanda
Journal:  Bone Marrow Transplant       Date:  2017-07-17       Impact factor: 5.483

2.  High-resolution HLA matching in unrelated donor transplantation in Switzerland: differential impact of class I and class II mismatches may reflect selection of nonimmunogenic or weakly immunogenic DRB1/DQB1 disparities.

Authors:  J R Passweg; U Schanz; Y Chalandon; T Güngör; H Baldomero; D Heim; G Nair; M Medinger; S Masouridi-Levrat; G N de Faveri; J-M Tiercy
Journal:  Bone Marrow Transplant       Date:  2015-06-08       Impact factor: 5.483

3.  Biological significance of HLA locus matching in unrelated donor bone marrow transplantation.

Authors:  Yasuo Morishima; Koichi Kashiwase; Keitaro Matsuo; Fumihiro Azuma; Satoko Morishima; Makoto Onizuka; Toshio Yabe; Makoto Murata; Noriko Doki; Tetsuya Eto; Takehiko Mori; Koichi Miyamura; Hiroshi Sao; Tatsuo Ichinohe; Hiroo Saji; Shunichi Kato; Yoshiko Atsuta; Keisei Kawa; Yoshihisa Kodera; Takehiko Sasazuki
Journal:  Blood       Date:  2014-12-17       Impact factor: 22.113

Review 4.  Hematopoietic stem cell transplantation for acute myeloid leukemia.

Authors:  Akiyoshi Takami
Journal:  Int J Hematol       Date:  2018-01-27       Impact factor: 2.490

Review 5.  Effect of HLA mismatch on acute graft-versus-host disease.

Authors:  Junya Kanda
Journal:  Int J Hematol       Date:  2013-07-28       Impact factor: 2.490

Review 6.  Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective.

Authors:  Masamitsu Yanada
Journal:  Int J Hematol       Date:  2014-09-12       Impact factor: 2.490

7.  Impact of HLA allele mismatch on the clinical outcome in serologically matched related hematopoietic SCT.

Authors:  S Fuji; J Kanda; S Kato; K Ikegame; S Morishima; T Miyamoto; M Hidaka; K Kubo; K Miyamura; K Ohashi; H Kobayashi; Y Maesako; S Adachi; T Ichinohe; Y Atsuta; Y Kanda
Journal:  Bone Marrow Transplant       Date:  2014-07-07       Impact factor: 5.483

8.  A comparison of tacrolimus and cyclosporine combined with methotrexate for graft-versus-host disease prophylaxis, stratified by stem cell source: a retrospective nationwide survey.

Authors:  Rika Sakai; Masataka Taguri; Kumi Oshima; Takehiko Mori; Hiroatsu Ago; Souichi Adachi; Satoshi Morita; Shuichi Taniguchi; Takahiro Fukuda; Kazuteru Ohashi; Tetsuya Eto; Koichi Miyamura; Koji Iwato; Naoki Kobayashi; Heiwa Kanamori; Yasuo Morishima; Tokiko Nagamura-Inoue; Hisashi Sakamaki; Yoshiko Atsuta; Makoto Murata
Journal:  Int J Hematol       Date:  2016-01-22       Impact factor: 2.490

Review 9.  How to select the best available related or unrelated donor of hematopoietic stem cells?

Authors:  Jean-Marie Tiercy
Journal:  Haematologica       Date:  2016-05-31       Impact factor: 9.941

10.  Identification of high-risk amino-acid substitutions in hematopoietic cell transplantation: a challenging task.

Authors:  S R Marino; S M Lee; T A Binkowski; T Wang; M Haagenson; H-L Wang; M Maiers; S Spellman; K van Besien; S J Lee; T Karrison; A Artz
Journal:  Bone Marrow Transplant       Date:  2016-05-23       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.